Trials / Terminated
TerminatedNCT00365820
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 670 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2006-08-18
- Last updated
- 2012-04-20
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00365820. Inclusion in this directory is not an endorsement.